Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Celera Group
A new study shows that the immune response to Pfizer/BioNTech’s Comirnaty in elderly people is 3.5-fold greater when the second dose is given after 12 weeks rather than three. The WHO has OKd the emergency use of a Chinese vaccine.
Promising early-stage data from two companies looking to break into crowded hemato-oncology markets.
PTC Therapeutics is one of many companies in the life sciences sector whose regulatory targets have been adversely affected by the coronavirus pandemic.
Market Snapshot: Acute myeloid leukemia is a serious condition that affects people mainly in late middle age, for which there is a large R&D pipeline of candidate products being researched by pharmaceutical and biotech companies, many of whom are using a targeted medicine approach.